On the 6th of May 2022, the Therapeutic Goods Administration (TGA) has granted provisional approval to Gilead Sciences PTY LTD to extend the use of VEKLURY(Remdesivir) as a treatment for Covid-19. The recipients will include paediatric patients from the age of 4 weeks.
Adults and children who develop pneumonia from Covid-19 and require supplemental oxygen will be administered the Remdesivir. Children must also be a minimum weight of 3 kilograms.
Adults and children who have a minimum weight of 40 kilograms and do not require oxygen but are declared a high risk of progressing to severe Covid-19 will also receive this treatment.
Provisional approval was first granted on the 10th of July 2020 for adults and adolescents over the age of twelve with a minimum weight of 40 kilograms who developed pneumonia and were placed in the hospital on oxygen. It was the first treatment option for Covid-19.
The World Health Organisation (WHO) did not recommend the use of Remdesivir on 20th November 2020 as evidence did not show any improvement in survival. On the 22nd of April 2022, the WHO changed it’s stance after clinical trials and recommends the use of this treatment in patients who have mild to moderate Covid-19 who are at a high risk of hospitalization.